Original Article

Antibiotic susceptibility profile of Pseudomonas species isolated from clinical specimens to access, watch and reserve drugs across various hospital settings at a tertiary care hospital of central India

Abstract

Background and Objectives: Over the last decade, hospital-acquired infections, particularly in the critical care setting, have become more common, with Gram-negative bacterial infections having the highest prevalence. This study aims to determine the prevalence and antibiotic susceptibility pattern of Pseudomonas species to WHO’s, aware class of antibiotics, which are commonly prescribed across various ICU’s, medical and surgical wards of our tertiary care teaching hospital.
Materials and Methods: This prospective study conducted from January 2021 to June 2022 at a tertiary care centre of central India identified Pseudomonas species from clinical samples using standard procedures and antimicrobial susceptibility testing performed as per Clinical Laboratory Standards Institute (CLSI) guidelines (M100; 32th Edition).
Results: A total of 1490 non duplicate Pseudomonas species isolates were grown from 21,019 culture positive clinical samples, of which 1247 were Pseudomonas aeruginosa. Out of these 1247 Pseudomonas aeruginosa 384 were MDR (30.7%). Pseudomonas aeruginosa were most commonly isolated from the pus samples (85%). ICU isolates were significantly more resistant to antibiotics than those from other units. P. aeruginosa strains from ICUs showed the highest rates of resistance to ceftazidime (93.9%). Reserve drug colistin showed good susceptibility (98.2%). All the 18 colistin resistant strains were found to be negative for plasmid mediated mcr-1,2,3 genes.
Conclusion: The study shall help to generate and disseminate the data so that proper antibiotic policy can be made for judicious use of Access, Watch and Reserve antibiotics and antibiotic de-escalation plan can be put forth.

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399: 629-655.
2. Pragasam AK, Veeraraghavan B, Nalini E, Anandan S, Kaye KS. An update on antimicrobial resistance and the role of newer antimicrobial agents for Pseudomonas aeruginosa. Indian J Med Microbiol 2018; 36: 303-316.
3. Ribeiro ÁCDS, Crozatti MTL, Silva AAD, Macedo RS, Machado AMO, Silva ATA. Pseudomonas aeruginosa in the ICU: Prevalence, resistance profile, and antimicrobial consumption. Rev Soc Bras Med Trop 2019; 53: e20180498.
4. Mandal P, Asad M, Kayal A, Biswas M. Assessment of use of World Health Organization access, watch, reserve antibiotics and core prescribing indicators in pediatric outpatients in a tertiary care teaching hospital in Eastern India. Perspect Clin Res 2023;14:61-67.
5. Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P, et al (2006). Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. 6th Edition, Lippincott Williams and Wilkins, New York.
6. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther 2022; 7: 199.
7. Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge. Emerg Microbes Infect 2022; 11: 811-814.
8. Daikos GL, da Cunha CA, Rossolini GM, Stone GG, Baillon-Plot N, Tawadrous M, et al. Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa. Antibiotics (Basel) 2021; 10: 1126.
9. Centers US, Control D. Antibiotic resistance threats in the United States, 2019.
10. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Van Duin D, Clancy CJ. Infectious diseases society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 2022; 75: 187-212.
11. Jorgensen JH, Pfaller MA, Carroll KC (2015). Manual of C linical Microbiology.
12. Clinical and Laboratory Standards Institute (CLSI). M100 Performance Standards for Antimicrobial Susceptibility Testing. M100-Ed31, Clinical and Laboratory Standards Institute (CLSI). 2021.
13. Test CS, Gram A, Bacteria N (2020). Broth - microdilution colistin susceptibility test for aerobic Gram - Negative bacteria standard operating procedure.
14. Soni M, Kapoor G, Perumal N, Chaurasia D. Emergence of multidrug-resistant Non-fermenting Gram-negative bacilli in a tertiary care teaching hospital of central India: is colistin resistance still a distant threat? Cureus 2023; 15(5): e39243.
15. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28: 108-121.
16. Maharjan N. Pseudomonas aeruginosa isolates among clinical samples showing growth in a tertiary care centre: A descriptive Cross-sectional study. JNMA J Nepal Med Assoc 2022; 60: 676-680.
17. Gupta R, Malik A, Rizvi M, Ahmed SM. Incidence of multidrug-resistant Pseudomonas spp. in ICU patients with special reference to ESBL, AMPC, MBL and biofilm production. J Glob Infect Dis 2016; 8: 25-31.
18. Stéphan F, Cheffi A, Bonnet F. Nosocomial infections and outcome of critically ill elderly patients after surgery. Anesthesiology 2001; 94: 407-414.
19. Nikokar I, Tishayar A, Flakiyan Z, Alijani K, Rehana-Banisaeed S, Hossinpour M, et al. Antibiotic resistance and frequency of class 1 integrons among pseudomonas aeruginosa, isolated from burn patients in Guilan, Iran. Iran J Microbiol 2013; 5: 36-41.
20. Feretzakis G, Loupelis E, Sakagianni A, Skarmoutsou N, Michelidou S, Velentza A, et al. A 2-year single-centre audit on antibiotic resistance of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae strains from an intensive care unit and other wards in a general public hospital in greece. Antibiotics (Basel) 2019; 8: 62.
21. Ayoub Moubareck C. Polymyxins and bacterial membranes: A review of antibacterial activity and mechanisms of resistance. Membranes (Basel) 2020; 10: 181.
Files
IssueVol 16 No 2 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v16i2.15348
Keywords
Antimicrobial drug resistance; Pseudomonas aeruginosa; Intensive care unit; Multidrug resistant; Colistin; World health organization
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Soni M, Chaurasia D, Kapoor G. Antibiotic susceptibility profile of Pseudomonas species isolated from clinical specimens to access, watch and reserve drugs across various hospital settings at a tertiary care hospital of central India. Iran J Microbiol. 2024;16(2):159-165.